The DIAPHRAGM study - biomarkers in MPM

In line with Glasgow’s cancer research strategy, which aims to define and implement personalised treatment strategies on the basis of the patient’s molecular phenotype, the Analytical Services Unit (ASU) at the Glasgow ECMC are leading the way in the development of novel biomarker assays.

Dr Kevin Blyth, in collaboration with respiratory physicians in Glasgow, has recently opened a new diagnostic biomarker study in mesothelinoma. The DIAPHRAGM study (Diagnostic and Prognostic biomarkers in the Rational Assessment of Mesothelioma) will obtain blood samples from patients attending a respiratory specialist to analyse the levels of two novel biomarkers: SOMAscan and/or Fibulin-3.

Researchers aim to define the biological basis of biomarker measurements and its clinical significance in separating patients with Malignant Pleural Mesothelioma (MPM) from other malignant pleural conditions and from people who have had previous asbestos exposure but show no evidence of MPM.
An exploratory sub-study will also be performed, in which the correlation between SOMAscan and Fibulin-3 levels in blood will be contrasted with enhanced Magnetic Resonance Imaging (MRI), to assess tumour volume and angiogenesis.